OSAKA -- Japanese drugmaker Shionogi announced on Monday that Chinese authorities have accepted its application filing to manufacture and sell Cefiderocol, used to treat antimicrobial-resistant infections for which existing antibiotics are ineffective.
Pharmaceuticals
Japan's Shionogi seeks China approval for superbug-fighting antibiotic
Cefiderocol drives drugmaker's overseas sales in U.S. and Europe
Shionogi launched Cefiderocol in the U.S. in 2020, with Japan approving the sale of the antibiotic in 2023. (Photo by Toshiki Sasazu)
Read Next
Latest on Pharmaceuticals
